Skip to content
drillr.ai
Sign up

ELAN

Elanco Animal Health, Inc.

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US

$23.24
+2.60%
Ask drillr

  • Oct 22, 2026, 23:59 UTC

    Elanco Animal Health appointed Jamie Preston as executive vice president and chief people officer, effective November 3, 2026; Dave Kinard intends to retire at year-end and will support the transition.

    Source:

  • Oct 15, 2026, 17:30 UTC

    Purdue University and Elanco Animal Health Inc broke ground on a planned 150,000-square-foot One Health Research Institute in Indianapolis.

    Source:

  • Sep 22, 2026, 23:59 UTC

    Bimeda launched MoxiSolv Pour-On (moxidectin), an FDA-approved topical parasiticide for beef and dairy cattle, as a bioequivalent alternative to Elanco's Cydectin Pour-On.

    Source:

  • Sep 11, 2026, 11:58 UTC

    Elanco Animal Health Incorporated announced that it will report its third quarter 2026 financial results on November 6, 2026.

    Source:

  • Aug 26, 2026, 12:30 UTC

    Elanco Animal Health completed a 25,000-square-foot expansion of its manufacturing facility in Elwood, Kansas, to boost monoclonal antibody production.

    Source:

  • Aug 24, 2026, 13:00 UTC

    Keystone Cooperative, an Indiana-based agricultural cooperative, joined Alloy Partners' One Health Studio as an advisory partner and invested an undisclosed amount, aiming to develop agrifood offerings at the intersection of animal, plant, and human health.

    Source:

  • Aug 7, 2026, 13:03 UTC

    Elanco's new drug for New World screwworm received emergency approval from the FDA.

    Source:

  • Aug 6, 2026, 21:58 UTC

    On August 6, 2026, Elanco Animal Health Inc's shares fell 7.7% to $24.20, contributing to a weekly decline of 8.5%.

    Source:

  • Aug 5, 2026, 10:27 UTC

    Elanco Animal Health reported second quarter 2026 revenue of $1,368 million, a 10% increase year-over-year, with reported net income of $54 million and adjusted EPS of $0.34.

    Source:

  • Jun 18, 2026, 11:26 UTC

    Elanco Animal Health Incorporated announced the launch of Elanco Ventures, a corporate venture capital platform, with a $25 million multi-year commitment to invest in animal health innovation.

    Source:

  • Jun 15, 2026, 12:47 UTC

    Elanco Animal Health Incorporated received USDA approval for TruCan Ultra Lyme-L4, the first and only 1/2 mL combination vaccine for Lyme and leptospirosis in dogs.

    Source:

  • Jun 4, 2026, 20:46 UTC

    Elanco completed the acquisition of AHV, strengthening its commitment to the global dairy industry.

    Source: